Exciting developments at the ASH Annual Meeting and Exposition

The 66th ASH Annual Meeting and Exposition will be held from 7–10 December 2024, in San Diego, California, with an online component. As the most extensive event in the field of hematology, this gathering offers unparalleled opportunities for learning, networking, and innovation. Participants can explore hundreds of sessions focusing on the latest trends and research in the discipline.

The event begins with preview days on 4 and 5 December, where attendees can familiarise themselves with the virtual platform, review session details, and customise their schedules. This virtual experience provides a comprehensive look at the programme and ensures participants can maximise their engagement during the main event.

Programming officially kicks off on 6 December with workshops, symposia, and trainee events. Notable activities include interactive discussions on emerging scientific developments, training sessions for program directors, and the highly anticipated ASH-a-Palooza, which offers mentorship and career development opportunities exclusively for trainees. Networking sessions such as the Trainee Welcome Reception add to the vibrant atmosphere, fostering connections among professionals in the field.

From 7–10 December, the main meeting schedule is packed with diverse offerings. There are oral abstract sessions, scientific symposia, and product presentations by industry leaders. Attendees can participate in career development lunches, special interest workshops, and interactive sessions such as “How I Treat” for clinically relevant discussions. Poster sessions and exhibitions also provide a platform to explore innovative research and new products in the hematology sector.

Highlights include the prestigious Ham-Wasserman Lecture, the Plenary Scientific Session, and the ASH Awards, recognising outstanding contributions to the field. Networking lounges, such as the Trainee Lounge, offer relaxed spaces for informal meetings and discussions. Complementing the in-person experience, the virtual platform ensures that all participants can revisit session recordings and catch up on content after the event.

The meeting concludes on 10 December, with virtual catch-up days from 11–13 December. These days provide access to recorded presentations and poster sessions, allowing attendees to reflect on and absorb the wealth of information shared during the meeting.

The ASH Annual Meeting continues to set the benchmark for educational and professional excellence in hematology. Whether attending in person or virtually, participants can look forward to a rich programme designed to inspire and advance the field.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn

More articles like this

Poolbeg receives US patent for Immunomodulator development

Poolbeg Pharma plc, a clinical-stage biopharmaceutical company, has announced that the US Patent Office will grant its US Immunomodulator I patent application. The patent covers POLB 001, a selective p38 MAP kinase inhibitor, and other similar

Poolbeg Pharma awarded POLB 001 patent in United States

Poolbeg Pharma plc (LON:POLB), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the US Patent Office has notified the Company of its official decision

AI in Pharmaceuticals

Artificial intelligence in the pharmaceutical industry has become central to modern drug discovery and development. Recognising both its potential and its risks, the FDA has initiated efforts to regulate AI’s role in the sector, balancing innovation

Poolbeg Pharma’s Oral GLP-1R agonist for metabolic disease

Poolbeg Pharma has developed a delivery system designed to enhance oral administration of GLP-1R agonists. This scalable, GRAS (Generally Recognised as Safe)-approved technology allows metabolic peptides to reach specific gut regions and enter systemic circulation, targeting

Poolbeg Pharma Scientist discusses Oral GLP-1 receptors

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

POLB 001: A promising treatment for severe influenza

Severe influenza is marked by an excessive immune response, which can cause considerable damage to the lungs and affect other organs. This uncontrolled reaction often leads to hospitalisation due to the impact it has on the

Advancements shaping the future of drug discovery

The landscape of drug discovery has long been known for its complexity and the substantial time and financial resources required to bring a single drug to the market. Traditional methods, while forming the backbone of the

Poolbeg Pharma patent portfolio significantly strengthened & expanded

Poolbeg Pharma plc (LON: POLB), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced its unaudited interim results for the six months to 30 June 2024.

UCD leads in research collaboration and Poolbeg Pharma partnership

University College Dublin (UCD) has been recognised for leading the way in research collaboration with industry in Ireland, according to Knowledge Transfer Ireland’s latest Annual Knowledge Transfer Survey (AKTS) for 2023. UCD, through its knowledge transfer

Cathal Friel on resilience, ambition and Ireland’s future

Business & Finance, established in 1964, is celebrating its 60th anniversary this year. To mark this milestone, the publication is conducting a series of Leadership interviews with influential figures shaping Ireland’s corporate landscape. One of these

AI’s impact on infectious disease drug development

Artificial intelligence (AI) represents a sophisticated form of machine learning capable of swiftly analysing extensive datasets, uncovering non-obvious patterns, and pinpointing novel disease targets along with potential drugs. AI is increasingly influencing drug development by identifying

Poolbeg Pharma’s innovative POLB001 demonstrates promising potential

Poolbeg Pharma plc, a forward-thinking biopharmaceutical company, has recently garnered attention for its groundbreaking work with POLB001, a novel therapeutic candidate showing significant promise in clinical research. As an emerging player in the pharmaceutical industry, Poolbeg